Towards a national program for Down syndrome and neural tube defect screening in the Netherlands

International Congress Series

Volumn 1279, Issue , 2005, Pages 213-220

  Schielen, P C J I ^a   Elvers, L H ^a   Loeber, J G ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

1st trimester test; Combined test; Down syndrome; Nuchal translucency; Risk calculation; Screening programme; Triple test

Indexed keywords

EID: 33646450817     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.12.054     Document Type: Article

References (15)

1. Cuckle H.S., Wald N.J., and Thompson S.G. Estimating a woman's risk of having a pregnancy associated with Down syndrome using her age and serum alpha-fetoprotein level. Br. J. Obstet. Gynaecol. 94 5 (1987) 387-402
2. Merkatz I.R., et al. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am. J. Obstet. Gynecol. 148 7 (1984) 886-894
3. Wald N.J., et al. Maternal serum screening for Down syndrome in early pregnancy. BMJ 297 6653 (1988) 883-887
4. Cuckle H.S., and van Lith J.M. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat. Diagn. 19 6 (1999) 505-512
5. Spencer K., et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-a. Ultrasound Obstet. Gynecol. 13 4 (1999 (Apr)) 231-237
6. Pandya P.P., et al. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br. J. Obstet. Gynaecol. 102 12 (1995) 957-962
7. Snijders R.J., et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 352 9125 (1998) 343-346
8. Position of the Dutch government concerning the report Prenatal screening (2) of the Dutch Health Council-Letter to the parliament of the state secretary for Health, Welfare, and Sports, June 7, 2004 (in Dutch).
9. Health Council of the Netherlands. Prenatal Sceening (2); Down syndrome, neural tube defects. The Hague: Health Council of the Netherlands, 2004; publication no. 2004/06 (in Dutch).
10. Schielen P.C.J.I., and Loeber J.G. Organisatie van een landelijk screeningsprogramma voor Downsyndroom en neuraalbuisdefecten. Ned. Tijdschr. Klin. Chemie Labgeneesk. 29 (2004) 188-191 (in Dutch)
11. Spencer K., et al. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?. Ultrasound Obstet. Gynecol. 22 (2004) 142-148
12. Cuckle H. MoM versus delta NT. Down's Screen. News 11 1 (2004) 40
13. Wald N.J., et al. Antenatal screening for Down syndrome. J. Med. Screen. 4 (1997) 181-246
14. Jones R. Screening software specifications. Down's Screen. News 9 2 (2002) 22-23
15. Palomaki G.E. Beyond truncation limits. Down's Screen. News 11 1 (2004) 36-37